Lon S. Schneider, MD, MS - Publications

Affiliations: 
Psychiatry and the Behavioral Sciences and Neurology University of Southern California, Los Angeles, CA, United States 
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=125
Website:
http://www.usc.edu/uscnews/experts/945.html

200 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Schneider LS, Hernandez G, Zhao L, Franke AA, Chen YL, Pawluczyk S, Mack WJ, Brinton RD. Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial. Menopause (New York, N.Y.). PMID 30889096 DOI: 10.1097/GME.0000000000001325  0.68
2019 Lee E, Gatz M, Tseng C, Schneider LS, Pawluczyk S, Wu AH, Deapen D. Evaluation of Medicare Claims Data as a Tool to Identify Dementia. Journal of Alzheimer's Disease : Jad. 67: 769-778. PMID 30689589 DOI: 10.3233/JAD-181005  0.68
2019 Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine. PMID 30643288 DOI: 10.1038/s41591-018-0297-y  0.32
2018 Klinger RY, James OG, Borges-Neto S, Bisanar T, Li YJ, Qi W, Berger M, Terrando N, Newman MF, Doraiswamy PM, Mathew JP, Weiner MW, Aisen P, Weiner M, Aisen P, ... ... Schneider LS, ... ... Schneider LS, et al. 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. Anesthesiology. PMID 29389750 DOI: 10.1097/ALN.0000000000002103  0.68
2017 Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, ... ... Schneider LS, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics. PMID 28714976 DOI: 10.1038/ng.3916  0.32
2016 Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimer's Research & Therapy. 8: 25. PMID 27358067 DOI: 10.1186/s13195-016-0194-x  0.88
2016 Bang J, Lobach IV, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Gold M, Morimoto BH, Boxer AL. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism & Related Disorders. PMID 27172829 DOI: 10.1016/j.parkreldis.2016.04.014  0.88
2016 Yesavage JA, Taylor JL, Friedman L, Rosenberg PB, Lazzeroni LC, Leoutsakos JS, Kinoshita LM, Perlow MJ, Munro CA, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, et al. Principal components analysis of agitation outcomes in Alzheimer's disease. Journal of Psychiatric Research. 79: 4-7. PMID 27115509 DOI: 10.1016/j.jpsychires.2016.04.004  0.88
2016 Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, et al. Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. The American Journal of Psychiatry. appiajp201615020248. PMID 27032628 DOI: 10.1176/appi.ajp.2016.15020248  0.88
2016 Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, ... ... Schneider LS, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/j.jalz.2016.02.002  0.88
2016 Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, ... ... Schneider LS, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet. Neurology. 15: 455-532. PMID 26987701 DOI: 10.1016/S1474-4422(16)00062-4  0.88
2016 Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, et al. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. The American Journal of Psychiatry. appiajp201515050648. PMID 26771737 DOI: 10.1176/appi.ajp.2015.15050648  0.68
2015 Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, et al. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. Journal of Psychiatric Research. 74: 17-21. PMID 26736036 DOI: 10.1016/j.jpsychires.2015.12.005  0.88
2015 Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26611790 DOI: 10.1007/s10928-015-9457-6  0.88
2015 Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, et al. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. International Psychogeriatrics / Ipa. 27: 2059-67. PMID 26305876 DOI: 10.1017/S1041610215001106  0.88
2015 Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. Journal of Geriatric Psychiatry and Neurology. PMID 26303700 DOI: 10.1177/0891988715601735  0.88
2015 Maust DT, Schneider LS, Kales HC. Estimating Mortality Associated With Antipsychotics and Other Psychotropics-Reply. Jama Psychiatry. 72: 1058. PMID 26287522 DOI: 10.1001/jamapsychiatry.2015.0675  0.88
2015 Ayton S, Faux NG, Bush AI. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nature Communications. 6: 6760. PMID 25988319 DOI: 10.1038/ncomms7760  0.88
2015 Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. Jama Psychiatry. 72: 438-45. PMID 25786075 DOI: 10.1001/jamapsychiatry.2014.3018  0.88
2015 Kim HM, Chiang C, Weintraub D, Schneider LS, Kales H. Treatment changes among older patients with dementia treated with antipsychotics. International Journal of Geriatric Psychiatry. PMID 25759986 DOI: 10.1002/gps.4281  0.88
2015 Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 84: 1121-7. PMID 25681452 DOI: 10.1212/WNL.0000000000001376  0.88
2015 Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics. 15: 83-105. PMID 25537424 DOI: 10.1586/14737175.2015.995637  0.88
2015 Ihl R, Bunevicius R, Frölich L, Winblad B, Schneider LS, Dubois B, Burns A, Thibaut F, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. International Journal of Psychiatry in Clinical Practice. 19: 2-7. PMID 25195764 DOI: 10.3109/13651501.2014.961931  0.88
2015 Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 24-31. PMID 24613705 DOI: 10.1016/j.jalz.2013.11.008  0.88
2015 Schneider LS. Introducing Alzheimer's & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer's Association Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 91-93. DOI: 10.1016/j.trci.2015.06.002  0.88
2015 Wang G, Kennedy RE, Cutter GR, Schneider LS. Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 63-71. DOI: 10.1016/j.trci.2015.03.002  0.88
2015 Kennedy RE, Cutter GR, Wang G, Schneider LS. Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 46-52. DOI: 10.1016/j.trci.2015.03.001  0.88
2015 Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 103-111. DOI: 10.1016/j.dadm.2014.11.003  0.88
2014 Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, ... ... Schneider LS, et al. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S430-52. PMID 25341459 DOI: 10.1016/j.jalz.2014.08.103  0.88
2014 Schneider LS. Idalopirdine for Alzheimer's disease: written in the stars. The Lancet. Neurology. 13: 1063-5. PMID 25297011 DOI: 10.1016/S1474-4422(14)70232-7  0.88
2014 Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, ... ... Schneider LS, et al. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 83: 364-73. PMID 24944261 DOI: 10.1212/WNL.0000000000000621  0.88
2014 Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, et al. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. Plos One. 9: e98426. PMID 24914549 DOI: 10.1371/journal.pone.0098426  0.88
2014 Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. The Lancet. Neurology. 13: 676-85. PMID 24873720 DOI: 10.1016/S1474-4422(14)70088-2  0.88
2014 Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. Journal of the American Geriatrics Society. 62: 985-8. PMID 24828933 DOI: 10.1111/jgs.12816  0.88
2014 Schneider LS. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 247-50. PMID 24698029 DOI: 10.1016/j.jalz.2013.12.002  0.88
2014 Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine. 275: 251-83. PMID 24605808 DOI: 10.1111/joim.12191  0.88
2014 Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Schneider LS, Skoog I, Kivipelto M. Advances in the prevention of Alzheimer's disease and dementia. Journal of Internal Medicine. 275: 229-50. PMID 24605807 DOI: 10.1111/joim.12178  0.88
2014 Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama. 311: 682-91. PMID 24549548 DOI: 10.1001/jama.2014.93  0.88
2014 Becker RE, Greig NH, Giacobini E, Schneider LS, Ferrucci L. A new roadmap for drug development for Alzheimer's disease. Nature Reviews. Drug Discovery. 13: 156. PMID 24362362 DOI: 10.1038/nrd3842-c2  0.88
2014 Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 22: 14-24. PMID 24314887 DOI: 10.1016/j.jagp.2013.02.014  0.88
2014 Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 349-59. PMID 23712001 DOI: 10.1016/j.jalz.2013.03.003  0.88
2013 Zhao L, Mao Z, Chen S, Schneider LS, Brinton RD. Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 37: 403-19. PMID 23948892 DOI: 10.3233/JAD-122341  0.88
2013 Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 438-44. PMID 23809364 DOI: 10.1016/j.jalz.2013.03.007  0.88
2013 Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. The American Journal of Psychiatry. 170: 651-9. PMID 23598969 DOI: 10.1176/appi.ajp.2012.12070927  0.88
2013 Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctôt KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 602-8. PMID 23562430 DOI: 10.1016/j.jalz.2012.12.001  0.88
2013 Schneider LS. Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneapolis, Minn.). 19: 339-57. PMID 23558481 DOI: 10.1212/01.CON.0000429180.60095.d0  0.88
2013 Schneider LS. Quantifying an amyloid β model for Alzheimer's disease. The Lancet. Neurology. 12: 327-8. PMID 23477990 DOI: 10.1016/S1474-4422(13)70050-4  0.88
2012 Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 1036-44. PMID 23032478 DOI: 10.1097/JGP.0b013e31826ce4c5  0.88
2012 Kennedy RE, Schneider LS, Cutter GR, Alzheimer's Disease Neuroimaging Initiative. Biomarker positive and negative subjects in the ADNI cohort: clinical characterization. Current Alzheimer Research. 9: 1135-41. PMID 22963265 DOI: 10.2174/156720512804142976  0.88
2012 Schneider LS. Ginkgo and AD: key negatives and lessons from GuidAge. The Lancet. Neurology. 11: 836-7. PMID 22959218 DOI: 10.1016/S1474-4422(12)70212-0  0.88
2012 Schneider LS. Recruitment methods for United States Alzheimer disease prevention trials. The Journal of Nutrition, Health & Aging. 16: 331-5. PMID 22499452 DOI: 10.1007/s12603-012-0011-6  0.88
2012 Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. The New England Journal of Medicine. 366: 957-9. PMID 22397659 DOI: 10.1056/NEJMe1200429  0.88
2012 Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006395. PMID 22393531 DOI: 10.1101/cshperspect.a006395  0.88
2012 Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, et al. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 121-30. PMID 22301195 DOI: 10.1016/j.jalz.2011.01.007  0.88
2012 Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. Risk of mortality among individual antipsychotics in patients with dementia. The American Journal of Psychiatry. 169: 71-9. PMID 22193526 DOI: 10.1176/appi.ajp.2011.11030347  0.88
2012 Schneider LS. Could cholinesterase inhibitors be harmful over the long term? International Psychogeriatrics / Ipa. 24: 171-4. PMID 22189623 DOI: 10.1017/S1041610211002389  0.88
2012 Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. The Journal of Clinical Psychiatry. 73: 121-8. PMID 21939611 DOI: 10.4088/JCP.10m06574  0.88
2012 Miller EA, Rosenheck RA, Schneider LS. Caregiver burden, health utilities, and institutional service use in Alzheimer's disease. International Journal of Geriatric Psychiatry. 27: 382-93. PMID 21560160 DOI: 10.1002/gps.2730  0.88
2012 Kales HC, Blow FC, Schneider LS. Response to Nasrallah Letter American Journal of Psychiatry. 169: 664-665. DOI: 10.1176/appi.ajp.2012.12020279r  0.88
2012 Schneider LS. Pharmacological treatment of Alzheimer's disease Advances in Biological Psychiatry. 28: 122-167. DOI: 10.1159/000335407  0.88
2011 Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D, et al. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. Journal of Geriatric Psychiatry and Neurology. 24: 222-8. PMID 22228829 DOI: 10.1177/0891988711422527  0.88
2011 Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR, Weiner MW, Thomas RG, Schneider LS, Tariot PN. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 77: 1263-71. PMID 21917762 DOI: 10.1212/WNL.0b013e318230a16c  0.88
2011 Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry. 68: 853-61. PMID 21810649 DOI: 10.1001/archgenpsychiatry.2011.72  0.88
2011 Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, ... ... Schneider LS, et al. IAGG workshop: health promotion program on prevention of late onset dementia. The Journal of Nutrition, Health & Aging. 15: 562-75. PMID 21808935 DOI: 10.1007/s12603-011-0142-1  0.88
2011 Zhao L, Mao Z, Schneider LS, Brinton RD. Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause (New York, N.Y.). 18: 1131-42. PMID 21738079 DOI: 10.1097/gme.0b013e3182175b66  0.88
2011 Schafer K, De Santi S, Schneider LS. Errors in ADAS-cog administration and scoring may undermine clinical trials results. Current Alzheimer Research. 8: 373-6. PMID 21557720 DOI: 10.2174/156720511795745357  0.88
2011 Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Archives of Neurology. 68: 991-8. PMID 21482915 DOI: 10.1001/archneurol.2011.69  0.88
2011 O'Halloran JP, Kemp AS, Salmon DP, Tariot PN, Schneider LS. Psychometric comparison of standard and computerized administration of the Alzheimer’s Disease Assessment Scale: Cognitive Subscale (ADASCog). Current Alzheimer Research. 8: 323-8. PMID 21314622 DOI: 10.2174/156720511795563692  0.88
2011 Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, Ignacio R, Ganoczy D, Cunningham F, Schneider LS, Blow FC. Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry. 68: 190-7. PMID 21300946 DOI: 10.1001/archgenpsychiatry.2010.200  0.88
2011 Golde TE, Schneider LS, Koo EH. Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 69: 203-13. PMID 21262461 DOI: 10.1016/j.neuron.2011.01.002  0.88
2011 Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Archives of Neurology. 68: 58-66. PMID 21220675 DOI: 10.1001/archneurol.2010.343  0.88
2011 Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology. 51: 1587-91. PMID 21209243 DOI: 10.1177/0091270010387604  0.88
2011 Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 76: 280-6. PMID 21178097 DOI: 10.1212/WNL.0b013e318207b1b9  0.88
2011 Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Disease and Associated Disorders. 25: 122-7. PMID 20921876 DOI: 10.1097/WAD.0b013e3181f883b7  0.88
2011 Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? International Journal of Geriatric Psychiatry. 26: 573-83. PMID 20672243 DOI: 10.1002/gps.2565  0.88
2011 Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. International Psychogeriatrics / Ipa. 23: 44-53. PMID 20214847 DOI: 10.1017/S1041610210000244  0.88
2011 Schneider LS, Kennedy RE, Cutter GR. Estimating power with effect size versus slop differences: Both means and variance matter Alzheimer's and Dementia. 7: 247-249. DOI: 10.1016/j.jalz.2011.02.003  0.88
2010 Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of Clinical Psychopharmacology. 30: 683-7. PMID 21105282 DOI: 10.1097/JCP.0b013e3181fa05bb  0.88
2010 Schneider LS. Organising the language of Alzheimer's disease in light of biomarkers. The Lancet. Neurology. 9: 1044-5. PMID 20934913 DOI: 10.1016/S1474-4422(10)70246-5  0.88
2010 Schneider LS, Kennedy RE, Cutter GR. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 367-77. PMID 20813339 DOI: 10.1016/j.jalz.2010.07.004  0.88
2010 Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 917-27. PMID 20808108 DOI: 10.1097/JGP.0b013e3181d5745d  0.88
2010 Miller EA, Rosenheck RA, Schneider LS. Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease. Alzheimer Disease and Associated Disorders. 24: 380-9. PMID 20625266 DOI: 10.1097/WAD.0b013e3181eb2f2e  0.88
2010 Schneider LS. Care plans for people with Alzheimer's disease. Bmj (Clinical Research Ed.). 340: c2626. PMID 20522658 DOI: 10.1136/bmj.c2626  0.88
2010 Schneider LS. The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. The Journal of Nutrition, Health & Aging. 14: 295-8. PMID 20305999 DOI: 10.1007/s12603-010-0066-1  0.88
2010 Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, ... ... Schneider LS, et al. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 89-97. PMID 20298968 DOI: 10.1016/j.jalz.2010.01.008  0.88
2010 Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 332-40. PMID 20220589 DOI: 10.1097/JGP.0b013e3181cc0333  0.88
2010 Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 136-45. PMID 20087081 DOI: 10.1097/JGP.0b013e3181c796eb  0.88
2010 Miller EA, Rosenheck RA, Schneider LS. Assessing the relationship between health utilities, quality of life, and health care costs in Alzheimer's disease: the CATIE-AD study. Current Alzheimer Research. 7: 348-57. PMID 19715552 DOI: 10.2174/156720510791162386  0.88
2009 Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama. 302: 2557-64. PMID 20009055 DOI: 10.1001/jama.2009.1866  0.88
2009 Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Disease and Associated Disorders. 23: 260-7. PMID 19812469 DOI: 10.1097/WAD.0b013e31819cb760  0.88
2009 Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 388-97. PMID 19751918 DOI: 10.1016/j.jalz.2009.07.038  0.88
2009 Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. The American Journal of Psychiatry. 166: 583-90. PMID 19369318 DOI: 10.1176/appi.ajp.2008.08081218  0.88
2009 Nelson JC, Delucchi K, Schneider LS. Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis. International Journal of Geriatric Psychiatry. 24: 539-44. PMID 19334041 DOI: 10.1002/gps.2233  0.88
2009 Schneider LS. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 172-9. PMID 19328454 DOI: 10.1016/j.jalz.2009.01.023  0.88
2009 Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, et al. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 85-92. PMID 19328434 DOI: 10.1016/j.jalz.2009.01.021  0.32
2009 Schneider LS, Lahiri DK. The perils of Alzheimer's drug development. Current Alzheimer Research. 6: 77-8. PMID 19199878 DOI: 10.2174/156720509787313871  0.88
2009 Miller EA, Schneider LS, Rosenheck RA. Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease. International Journal of Geriatric Psychiatry. 24: 96-105. PMID 19016254 DOI: 10.1002/gps.2160  0.88
2009 Schneider LS, Zheng L, Mack WJ. Drs. Schneider, Zheng, and Mack reply American Journal of Psychiatry. 166: 1064-1065. DOI: 10.1176/appi.ajp.2009.09040544r  0.88
2009 Aisen PS, Schneider LS, Sano M. High-dose B vitamin supplements and alzheimer disease reply Jama - Journal of the American Medical Association. 301: 1021-1022. DOI: 10.1001/jama.2009.213  0.88
2008 Schneider LS. Ginkgo biloba extract and preventing Alzheimer disease. Jama. 300: 2306-8. PMID 19017919 DOI: 10.1001/jama.2008.675  0.88
2008 Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. Jama. 300: 1774-83. PMID 18854539 DOI: 10.1001/jama.300.15.1774  0.88
2008 Schneider LS. Prevention therapeutics of dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: S122-30. PMID 18631988 DOI: 10.1016/j.jalz.2007.11.005  0.88
2008 Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 156-63. PMID 18631960 DOI: 10.1016/j.jalz.2008.03.005  0.88
2008 Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 558-67. PMID 18591576 DOI: 10.1097/JGP.0b013e3181693288  0.88
2008 Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. The American Journal of Psychiatry. 165: 844-54. PMID 18519523 DOI: 10.1176/appi.ajp.2008.07111779  0.88
2008 Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 469-77. PMID 18515691 DOI: 10.1097/JGP.0b013e318165dbae  0.88
2008 Miller EA, Schneider LS, Zbrozek A, Rosenheck RA. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 1120-30. PMID 18489496 DOI: 10.1111/j.1524-4733.2008.00351.x  0.88
2008 Schneider LS. Does donepezil improve executive function in patients with CADASIL? The Lancet. Neurology. 7: 287-9. PMID 18296122 DOI: 10.1016/S1474-4422(08)70047-4  0.88
2008 Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology. 48: 157-65. PMID 18199892 DOI: 10.1177/0091270007310385  0.88
2008 O'Halloran JP, Kemp AS, Gooch KN, Harvey PD, Palmer BW, Reist C, Schneider LS. Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia. Schizophrenia Research. 106: 33-41. PMID 18160262 DOI: 10.1016/j.schres.2007.11.015  0.88
2008 Schneider LS. Issues in design and conduct of clinical trials for cognitive-enhancing drugs Animal and Translational Models For Cns Drug Discovery. 2: 21-76. DOI: 10.1016/B978-0-12-373861-5.00014-X  0.88
2008 Yaari R, Tariot PN, Schneider LS, Roose SP. Cognitive Enhancers and Treatments for Alzheimer's Disease Psychiatry: Third Edition. 2: 2294-2317. DOI: 10.1002/9780470515167.ch107  0.88
2007 Schneider LS. Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Wuthering forest plots: distinguishing the forest from the plots. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 3: 18-20. PMID 19595911 DOI: 10.1016/j.jalz.2006.10.003  0.88
2007 Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. The American Journal of Psychiatry. 164: 5-56. PMID 18340692  0.88
2007 Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Archives of General Psychiatry. 64: 1259-68. PMID 17984395 DOI: 10.1001/archpsyc.64.11.1259  0.88
2007 Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet. Neurology. 6: 782-92. PMID 17689146 DOI: 10.1016/S1474-4422(07)70195-3  0.88
2007 Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics. Current Alzheimer Research. 4: 325-35. PMID 17627490 DOI: 10.2174/156720507781077214  0.88
2007 Winstein CJ, Bentzen KR, Boyd L, Schneider LS. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Current Alzheimer Research. 4: 273-6. PMID 17627484 DOI: 10.2174/156720507781077296  0.88
2007 Schneider LS, Tariot PN, Weintraub D. The authors reply [3] New England Journal of Medicine. 356: 417-418.  0.88
2006 Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Disease and Associated Disorders. 20: S124-38. PMID 17135806 DOI: 10.1097/01.wad.0000213878.47924.44  0.88
2006 Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG. Design of Depression in Alzheimer's Disease Study-2. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 920-30. PMID 17068314 DOI: 10.1097/01.JGP.0000240977.71305.ee  0.88
2006 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine. 355: 1525-38. PMID 17035647 DOI: 10.1056/NEJMoa061240  0.88
2006 Schneider LS. Open-label extension studies and misinformation. Archives of Neurology. 63: 1036; author reply 1. PMID 16831980 DOI: 10.1001/archneur.63.7.1036-a  0.88
2006 Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, Gharabawi G, Schneider LS. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 280-91. PMID 16505133 DOI: 10.1097/01.JGP.0000194643.63245.8c  0.88
2006 Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 191-210. PMID 16505124 DOI: 10.1097/01.JGP.0000200589.01396.6d  0.88
2006 Schneider LS. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? International Journal of Geriatric Psychiatry. 21: 9-13. PMID 16353164 DOI: 10.1002/gps.1492  0.88
2006 Schneider LS, Dagerman KS, Insel P. In reply [4] Journal of the American Medical Association. 295: 496-497. DOI: 10.1001/jama.295.5.496-b  0.88
2005 McShane R, Schneider LS. Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 1: 67-71. PMID 19595819 DOI: 10.1016/j.jalz.2005.06.025  0.88
2005 Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Current Alzheimer Research. 2: 541-51. PMID 16375657  0.88
2005 Schneider LS. Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment. Alzheimer Disease and Associated Disorders. 19: 279-83. PMID 16327360 DOI: 10.1097/01.wad.0000190808.97878.b8  0.88
2005 Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. 294: 1934-43. PMID 16234500 DOI: 10.1001/jama.294.15.1934  0.88
2005 Schneider LS. Mild cognitive impairment. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 13: 629-32. PMID 16085778 DOI: 10.1176/appi.ajgp.13.8.629  0.88
2005 Nelson JC, Clary CM, Leon AC, Schneider LS. Symptoms of late-life depression: frequency and change during treatment. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 13: 520-6. PMID 15956272 DOI: 10.1176/appi.ajgp.13.6.520  0.88
2005 Rosenberg PB, Onyike CU, Katz IR, Porsteinsson AP, Mintzer JE, Schneider LS, Rabins PV, Meinert CL, Martin BK, Lyketsos CG. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. International Journal of Geriatric Psychiatry. 20: 119-27. PMID 15660424 DOI: 10.1002/gps.1261  0.88
2004 Jackson-Siegal JM, Schneider LS, Baskys A, Haupt DW. Recognizing and responding to atypical antipsychotic side effects. Journal of the American Medical Directors Association. 5: H7-10. PMID 15243311 DOI: 10.1016/S1525-8610(04)70141-3  0.88
2004 Schneider LS. AD2000: donepezil in Alzheimer's disease. Lancet. 363: 2100-1. PMID 15220027 DOI: 10.1016/S0140-6736(04)16533-1  0.88
2004 Schneider LS. Estrogen and dementia: insights from the Women's Health Initiative Memory Study. Jama. 291: 3005-7. PMID 15213214 DOI: 10.1001/jama.291.24.3005  0.88
2004 Schneider LS, Qizilbash N. Delay in nursing home placement with donepezil. Journal of the American Geriatrics Society. 52: 1024-6; author reply. PMID 15161477 DOI: 10.1111/j.1532-5415.2004.52277_3.x  0.88
2004 Carroll BJ. Sertraline and the Cheshire cat in geriatric depression. The American Journal of Psychiatry. 161: 759; author reply 75. PMID 15056533  0.88
2004 Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. Journal of Psychiatric Research. 38: 105-11. PMID 14690773 DOI: 10.1016/S0022-3956(03)00092-X  0.88
2004 Schneider LS. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents: Commentary Evidence-Based Mental Health. 7: 47. DOI: 10.1136/ebmh.7.2.47  0.88
2003 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, et al. Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Review of Neurotherapeutics. 3: 99-106. PMID 19810852 DOI: 10.1586/14737175.3.1.99  0.88
2003 Bartels SJ, Dums AR, Oxman TE, Schneider LS, Areán PA, Alexopoulos GS, Jeste DV. Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses. The Psychiatric Clinics of North America. 26: 971-90, x-xi. PMID 14711131 DOI: 10.1016/S0193-953X(03)00072-8  0.88
2003 Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. The Journal of Clinical Psychiatry. 64: 1065-74. PMID 14628982  0.88
2003 Schneider LS. Cholinesterase inhibitors for vascular dementia? The Lancet. Neurology. 2: 658-9. PMID 14572732 DOI: 10.1016/S1474-4422(03)00581-7  0.88
2003 Schneider LS, Porsteinsson AP, Peskin ER, Pfeiffer EA. Choosing treatment for Alzheimer's patients and their caregivers. Geriatrics. 58: 3-18, 23; quiz 19-22. PMID 12961833  0.88
2003 Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bulletin. 29: 57-72. PMID 12908661  0.88
2003 Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 11: 414-25. PMID 12837670 DOI: 10.1097/00019442-200307000-00004  0.88
2003 Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. The American Journal of Psychiatry. 160: 1277-85. PMID 12832242 DOI: 10.1176/appi.ajp.160.7.1277  0.88
2003 Schneider LS. Cholinesterase inhibitors for Alzheimer disease. Jama. 289: 2359-60; author repl. PMID 12746354 DOI: 10.1001/jama.289.18.2359-c  0.88
2003 van Gool WA, Lemstra AW. Cholinesterase inhibitors for Alzheimer disease. Jama. 289: 2359; author reply 2. PMID 12746352 DOI: 10.1001/jama.289.18.2359-a  0.88
2003 Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Current Drug Targets. 4: 97-112. PMID 12558063 DOI: 10.2174/1389450033346957  0.88
2003 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand OP, Jeste DV, Krishnan KRR, Lyketsos CG, Lyness JM, Rabins PV, et al. Diagnostic criteria for Depression of Alzheimer disease (DAD) Research and Practice in Alzheimer's Disease. 7: 174-179.  0.88
2003 Schneider LS. Potential noncholinnergic strategies for Alzheimer's disease Geriatrics. 58: 4-8.  0.88
2002 Finucane TE, Schneider LS. Cholinesterase inhibitors for Alzheimer's disease [3] (multiple letters) Lancet. 360: 1332-1333. PMID 12414234  0.88
2002 Bartels SJ, Dums AR, Oxman TE, Schneider LS, Areán PA, Alexopoulos GS, Jeste DV. Evidence-based practices in geriatric mental health care. Psychiatric Services (Washington, D.C.). 53: 1419-31. PMID 12407270 DOI: 10.1176/appi.ps.53.11.1419  0.88
2002 Olin JT, Dagerman KS, Fox LS, Bowers B, Schneider LS. Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Disease and Associated Disorders. 16: S82-5. PMID 12351920  0.88
2002 Tractenberg RE, Gamst A, Thomas RG, Patterson M, Schneider LS, Thal LJ. Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 14: 303-10. PMID 12154155 DOI: 10.1176/appi.neuropsych.14.3.303  0.88
2002 Schneider LS, Small GW. The increasing power of placebos in trials of antidepressants. Jama. 288: 450. PMID 12132971  0.88
2002 Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 129-41. PMID 11925274  0.88
2002 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, et al. Provisional diagnostic criteria for depression of Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 125-8. PMID 11925273 DOI: 10.1097/00019442-200203000-00003  0.88
2001 Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 400-5. PMID 11739066  0.88
2001 Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 346-60. PMID 11739062 DOI: 10.1097/00019442-200111000-00004  0.88
2001 Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Disease and Associated Disorders. 15: S8-18. PMID 11669509  0.88
2001 Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider LS. Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clinics in Geriatric Medicine. 17: 359-76. PMID 11375140 DOI: 10.1016/S0749-0690(05)70073-2  0.88
2000 Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 55: 1271-8. PMID 11087767  0.88
2000 Tractenberg RE, Jin S, Patterson M, Schneider LS, Gamst A, Thomas RG, Thal LJ. Qualifying change: a method for defining clinically meaningful outcomes of change score computation. Journal of the American Geriatrics Society. 48: 1478-82. PMID 11083327  0.88
1999 Ippen CG, Olin JT, Schneider LS. Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients?: A longitudinal analysis. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 7: 321-30. PMID 10521165  0.88
1998 Fox LS, Olin JT, Erblich J, Ippen CG, Schneider LS. Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT). International Journal of Geriatric Psychiatry. 13: 544-9. PMID 9733335 DOI: 10.1002/(SICI)1099-1166(199808)13:8<544::AID-GPS821>3.0.CO;2-N  0.88
1998 Schneider LS. Advances in the treatment of Alzheimer's disease. Aging (Milan, Italy). 10: 156-7. PMID 9666210  0.88
1997 Schneider LS, Farlow MR, Pogoda JM. Potential role for estrogen replacement in the treatment of Alzheimer's dementia. The American Journal of Medicine. 103: 46S-50S. PMID 9344406 DOI: 10.1016/S0002-9343(97)00257-X  0.88
1997 Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. Jama. 278: 1363-71. PMID 9343469  0.32
1997 Lebowitz BD, Pearson JL, Schneider LS, Reynolds CF, Alexopoulos GS, Bruce ML, Conwell Y, Katz IR, Meyers BS, Morrison MF, Mossey J, Niederehe G, Parmelee P. Diagnosis and treatment of depression in late life. Consensus statement update. Jama. 278: 1186-90. PMID 9326481  0.88
1997 Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. Journal of the American Geriatrics Society. 45: 923-8. PMID 9256842  0.88
1997 Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S51-6. PMID 9236953  0.88
1997 Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S22-32. PMID 9236949  0.88
1997 Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S1-12. PMID 9236947  0.88
1997 Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. The New England Journal of Medicine. 336: 1216-22. PMID 9110909 DOI: 10.1056/NEJM199704243361704  0.88
1996 Schneider LS, Olin JT. Clinical global impressions in Alzheimer's clinical trials. International Psychogeriatrics / Ipa. 8: 277-88; discussion 2. PMID 8994897 DOI: 10.1017/S1041610296002645  0.88
1996 Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. Journal of Geriatric Psychiatry and Neurology. 9: 176-80. PMID 8970010  0.88
1996 Schneider LS. Overview of generalized anxiety disorder in the elderly. The Journal of Clinical Psychiatry. 57: 34-45; discussion 52. PMID 8690696  0.88
1996 Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 46: 1580-4. PMID 8649552  0.88
1995 Schneider LS, Olin JT. Efficacy of acute treatment for geriatric depression. International Psychogeriatrics / Ipa. 7: 7-25. PMID 8580394 DOI: 10.1017/S1041610295002328  0.88
1995 Holt LE, Raine A, Pa G, Schneider LS, Henderson VW, Pollock VE. P300 topography in Alzheimer's disease. Psychophysiology. 32: 257-65. PMID 7784534 DOI: 10.1111/j.1469-8986.1995.tb02954.x  0.88
1995 Lebowitz BD, Martinez RA, Niederehe G, Pearson JL, Reynolds CF, Rudorfer MV, Schneider LS, Kupfer DJ. NIMH/MacArthur Foundation workshop report. Treatment of depression in late life. Psychopharmacology Bulletin. 31: 185-202. PMID 7675983  0.88
1994 Lyness SA, Eaton EM, Schneider LS. Cognitive performance in older and middle-aged depressed outpatients and controls. Journal of Gerontology. 49: P129-36. PMID 8169342  0.88
1994 Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Archives of Neurology. 51: 787-98. PMID 8042927 DOI: 10.1001/archneur.1994.00540200063018  0.88
1993 Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. The American Journal of Psychiatry. 150: 321-3. PMID 8422085  0.88
1992 Schneider LS. Tracking dementia by the IMC and the MMSE. Journal of the American Geriatrics Society. 40: 537-8. PMID 1634715  0.88
1992 Pollock VE, Schneider LS, Zemansky MF, Gleason RP, Pawluczyk S. Topographic quantitative EEG amplitude in recovered alcoholics. Psychiatry Research. 45: 25-32. PMID 1410076  0.68
1992 Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. The New England Journal of Medicine. 327: 1253-9. PMID 1406817 DOI: 10.1056/NEJM199210293271801  0.88
1991 Schneider LS, Lyness SA, Pawluczyk S, Gleason RP, Sloane RB. Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report. Psychopharmacology Bulletin. 27: 309-14. PMID 1775604  0.68
1990 Schneider LS, Cooper TB, Suckow RF, Lyness SA, Haugen C, Palmer R, Sloane RB. Relationship of hydroxynortriptyline to nortriptyline concentration and creatinine clearance in depressed elderly outpatients. Journal of Clinical Psychopharmacology. 10: 333-7. PMID 2258449  0.88
1989 Kramer BA, Pollock VE, Schneider LS, Gray GE. Interrater reliability of MECTA SR-1 seizure duration. Biological Psychiatry. 25: 642-4. PMID 2920198 DOI: 10.1016/0006-3223(89)90228-X  0.88
1989 Henderson VW, Roberts E, Wimer C, Bardolph EL, Chui HC, Damasio AR, Eslinger PJ, Folstein MF, Schneider LS, Teng EL. Multicenter trial of naloxone in Alzheimer's disease. Annals of Neurology. 25: 404-6. PMID 2653175 DOI: 10.1002/ana.410250413  0.88
1989 Kramer BA, Pollock VG, Schneider LS, Gray GE. ECT seizure monitoring. Biological Psychiatry. 26: 848-50. PMID 2590696 DOI: 10.1016/0006-3223(89)90126-1  0.88
1987 Teng EL, Chui HC, Schneider LS, Metzger LE. Alzheimer's dementia: performance on the Mini-Mental State Examination. Journal of Consulting and Clinical Psychology. 55: 96-100. PMID 3571664  0.88
1987 Schneider LS, Syapin PJ, Pawluczyk S. Seizures following triazolam withdrawal despite benzodiazepine treatment. The Journal of Clinical Psychiatry. 48: 418-9. PMID 2889721  0.68
1986 Schneider LS, Severson JA, Pollock V, Cowan RP, Sloane RB. Platelet monoamine oxidase activity in elderly depressed outpatients. Biological Psychiatry. 21: 1360-4. PMID 3790624 DOI: 10.1016/0006-3223(86)90327-6  0.88
1985 Schneider LS, Eth S. Observations on misdiagnosis of rabies. Psychosomatics. 26: 338-40. PMID 3991865 DOI: 10.1016/S0033-3182(85)72867-8  0.88
Show low-probability matches.